Kenneth R. Deans Jr.
South Carolina
Kenneth R. Deans Jr. is a Contributing Writer for The American Quorum. With 30+ years of leadership across healthcare, technology, and education, he brings an experienced, independent perspective to issues shaping America.
Healthcare
FDA and CDC Open Second mRNA Boosters to Americans 50 and Older as Evidence Points to Waning Protection
Tech
Amazon Workers Vote 2,654–2,131 for Union at JFK8, Delivering First U.S. Organizing Victory at Retail Giant
Healthcare
Moderna Says Two 25-Microgram Doses Met Immune Endpoint in Children Under 6 as Omicron Limits Infection Protection
Tech
EU Strikes Digital Markets Act Deal, Threatening Big Platforms With Fines Up to 20% of Global Revenue
Healthcare
Moderna Seeks Second COVID-19 Booster for All Adults as U.S. Weighs How Long Third-Dose Protection Lasts
Tech
Amazon Closes $8.45 Billion MGM Deal, Adding 4,000 Films and 17,000 TV Episodes to Streaming Arsenal
Healthcare
Congress Drops $15.6 Billion in COVID Aid From Spending Bill as White House Warns Supplies Could Tighten
Tech
Google Agrees to Buy Mandiant for $5.4 Billion, Making Cybersecurity a Bigger Cloud Battleground
Healthcare
White House COVID Plan Shifts U.S. Toward Test-to-Treat Strategy as Omicron Wave Recedes
Tech
Microsoft Suspends New Sales in Russia as Global Technology Companies Deepen Commercial Pullback
Healthcare
CDC Shifts Mask Guidance to Hospital Burden, Leaving Most Americans Outside Indoor-Mask Recommendation
Tech
U.S. Export Controls Cut Russia Off From Advanced Chips as Global Technology Restrictions Take Hold
Healthcare
CDC Finds Booster Protection Waning by Four Months as Omicron Drives 99% of U.S. Infections
Tech
Intel Agrees to Buy Tower Semiconductor for $5.4 Billion to Accelerate Foundry Expansion
Healthcare
FDA Delays Review of Pfizer COVID-19 Vaccine for Children Under 5 to Await Third-Dose Data
Tech
Nvidia and SoftBank Abandon $40 Billion Arm Deal After U.S. and U.K. Regulators Challenge Chip Merger
Healthcare
Pfizer Seeks COVID-19 Vaccine Authorization for Children Under 5 as FDA Sets February Review
401 stories